Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703094 | 1.00 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3668278 | 0.89 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13154228 | 0.88 | ESR2 (0.64) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2047764 | 0.80 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2150278 | 0.80 | ESR2 (0.78) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7004274 | 0.80 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14144935 | 0.80 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL444141 | 0.80 | SRD5A1 (0.53) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2150282 | 0.80 | ESR2 (0.78) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2046091 | 0.80 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-11058696-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058696-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3183242-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-10709719-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20110245204-A1 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-10-06 | — | — | US | disclosed |
| US-20110245204-A1 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-10-06 | — | — | US | disclosed |
| US-8008286-B2 | Method for treatment of neuropathic pain | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-30 | — | — | US | disclosed |
| US-7754703-B2 | Cycloalkane-containing sphingosine 1-phosphate agonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090062238-A1 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2009-03-05 | — | — | US | disclosed |
| EP-1986623-A2 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080249070-A1 | Cycloalkane-Containing Sphingosine 1-Phospate Agonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| EP-1863463-A1 | SPHINGOSINE 1-PHOSPHATE AGONISTS COMPRISING CYCLOALKANES AND 5-MEMBERED HETEROCYCLES SUBSTITUED BY AMINO AND PHENYL GROUPS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007089715-A2 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006088944-A1 | SPHINGOSINE 1- PHOS PHATE AGONISTS COMPRISING CYCLOALKANES AND 5 -MEMBERED HETEROCYCLES SUBSTITUTED BY AMINO AND PHENYL GROUPS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245204-A1 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS | S1PR1, S1PR3, S1PR4 | ESR2 2108/4885PDE4A 320/4885PDE4B 488/4885 |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | ESR2 715/4885PDE4A 192/4885PDE4B 274/4885 |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | ESR2 715/4885PDE4A 192/4885PDE4B 274/4885 |
| US-11701373-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | ESR2 715/4885PDE4A 192/4885PDE4B 274/4885 |
| US-20090062238-A1 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | S1PR2, S1PR1, S1PR4 | ESR2 1983/4885PDE4A 199/4885PDE4B 345/4885 |
| US-11058696-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | ESR2 715/4885PDE4A 192/4885PDE4B 274/4885 |
| US-20080249070-A1 | Cycloalkane-Containing Sphingosine 1-Phospate Agonists | S1PR1, S1PR3, S1PR4 | ESR2 2257/4885PDE4A 371/4885PDE4B 597/4885 |
| US-10709719-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | ESR2 715/4885PDE4A 192/4885PDE4B 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.